---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-24-000021"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:42:10.414290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M

## Summary
- Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).
- Adjusted gross margin expanded to 61% from 34% YoY; exome/genome margin above 65%.
- Adjusted net loss narrowed to $8.5M (83% YoY improvement); GAAP net loss $20.2M.
- Cash burn reduced 71% YoY to $17.2M; cash position $113.9M as of March 31.
- Raised FY 2024 revenue guidance to $235-245M; reiterate path to profitability in 2025.

## SEC filing metadata
- accession: 0001818331-24-000021
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/wgs-20240429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-24-000021
- JSON: https://secwatch.observer/filing/0001818331-24-000021.json
- Plain text: https://secwatch.observer/filing/0001818331-24-000021.txt

## Key facts
- Earnings Releases
  GeneDx Holdings Corp. reported quarter ended March 31, 2024 results: revenue $61.5 million, net income $8.5 million. Guidance raised.
  - Period: quarter ended March 31, 2024
  - Revenue: $61.5 million
  - Net income: $8.5 million
  - Guidance: raised
  - Result: reported results
  source text: and reiterate our expectation to reach profitability in 2025.” First Quarter 2024 Financial Results (Unaudited) 1,2 Revenues • Revenues from continuing operations grew to $61.5 million, an increase of 51% year-over-year and 6% sequentially. ◦ Total company revenues were $62.4 million. • Exome and genome test revenue grew to $44.0 million, an increase of 96%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000021/0001818331-24-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.